Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w.
We are pleased to enclose a Press Release as regards, receipt of U.S. FDA approval for the Company’s Abbreviated New Drug Application, Diclofenac Sodium Topical Solution USP, 2% w/w to market a generic equivalent of Pennsaid ® Topical Solution, 2% w/w of Horizon Pharma Ireland DAC.
Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Diclofenac Sodium Topical Solution USP, 2% w/w to market a generic equivalent of Pennsaid® Topical Solution, 2% w/w of Horizon Pharma Ireland DAC.
Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Mentioned Phrases & Organizations
Important keywords detected (20+)
Organizations identified (9+)
Features are experimental.